Neuland Laboratories
Market cap ₹27,527 Cr
- P/E
- 60.83
- Day range
- ₹21,060.00 – ₹21,661.00
- 52-week range
- ₹11,500.00 – ₹24,225.00
- Volume
- 45,676
- Open
- ₹21,200.00
- Prev close
- ₹21,445.00
Latest results · Q2 FY27(consolidated)Revenue ₹450 Cr-12.6%Profit ₹52 Cr-46.7%Margin 11.5%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter pledge went up
2.32% of promoter shares pledged, up from 2.29% · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
NEULANDLAB in NSE indices and F&O
Research profile
Composite 51 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.6%
- Graham no.
- ₹3,526.75
- vs Graham
- -83.6%
- ROE ÷ P/B
- 1.6%
- 12-1 mom.
- +8.6%
- Return / vol
- 0.50
- Magic Formula
- #338
- Piotroski
- 2/6
- FCF yield
- -0.2%
Appears in 11 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Neuland LaboratoriesNEULANDLAB | ₹27,527 Cr | 60.83 | 13.68 | 21.4% | 26.0% | 22.0% | 0.17 | -12.5% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 8d agoHeadlines about Neuland Laboratories from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 61.4
- Price / Book
- 13.56
- ROE (FY26)
- 21.4%
- ROCE (latest year)
- 26%
- Dividend yield
- 0.16%
Moving averages (NSE)
- 20-day
- ₹19,961
- Price above
- 50-day
- ₹21,088.6
- Price above
- 200-day
- ₹17,782.66
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- FII
- DII
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 | 450 |
| YoY Sales growth | — | -5 | — | -26 | — | -15 | -33 | — | — | — | — | -13 |
| Expenses | 272 | 278 | 316 | 249 | 311 | 277 | 258 | 359 | 363 | 469 | 419 | 352 |
| Operating Profit | 121 | 107 | 123 | 62 | 87 | 51 | 34 | 156 | 77 | 307 | 223 | 98 |
| OPM % | 31% | 28% | 28% | 20% | 22% | 16% | 12% | 30% | 18% | 40% | 35% | 22% |
| Other Income | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 | 8 |
| Interest | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 | 7 |
| Depreciation | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 | 29 |
| Profit before tax | 104 | 92 | 130 | 49 | 128 | 39 | 18 | 129 | 54 | 287 | 198 | 69 |
| Tax % | 22% | 27% | 25% | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% | 25% |
| Net Profit | 81 | 68 | 98 | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 | 52 |
| EPS in Rs | ₹63.44 | ₹52.66 | ₹76.28 | ₹25.60 | ₹79.18 | ₹21.68 | ₹10.83 | ₹75.49 | ₹31.62 | ₹165.76 | ₹115.10 | ₹40.24 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+13 days since Mar 2021
+40 days since Mar 2021
+3 days since Mar 2021
+50 days since Mar 2021
+15 days since Mar 2021
Strengths, risks & growth
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. [1]
Strengths
- Company is expected to give good quarter
- Company has delivered good profit growth of 38.5% CAGR over last 5 years
Risks
- Stock is trading at 13.7 times its book value
- Promoter holding has decreased over last quarter: -0.36%
Compounded Sales Growth
- 10 Years
- +15%
- 5 Years
- +17%
- 3 Years
- +19%
- TTM
- +50%
Compounded Profit Growth
- 10 Years
- +29%
- 5 Years
- +39%
- 3 Years
- +30%
- TTM
- +131%
Stock Price CAGR
- 10 Years
- +36%
- 5 Years
- +67%
- 3 Years
- +59%
- 1 Year
- +25%
Return on Equity
- 10 Years
- +14%
- 5 Years
- +18%
- 3 Years
- +20%
- Last Year
- +21%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 32.63% | 32.63% | 32.62% | 32.26% | -0.36 pp |
| FII | 20.90% | 20.46% | 21.08% | 21.93% | +0.85 pp |
| DII | 14.72% | 15.84% | 16.52% | 16.25% | -0.27 pp |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 pp |
| Public | 31.76% | 31.08% | 29.79% | 29.55% | -0.24 pp |
Filed with NSE for Sept 2026: promoters 32.26%, public 67.74%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 12.45% (-0.21 pp)- Promoters32.3%
- Foreign institutions21.9%
- Mutual funds12.4%
- Insurance1.4%
- Other domestic institutions2.5%
- Retail15.7%
- Others13.8%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Flexi Cap Fund | 2.27% | 0.58% | +0.31 pp |
| HSBC Small Cap Fund | 1.15% | 1.84% | +0.11 pp |
| ICICI Pru Flexi Cap Fund | 1.05% | 1.14% | -0.64 pp |
| Mahindra Manulife Multi Cap Fund | 0.68% | 2.56% | -0.98 pp |
| Mahindra Manulife Small Cap Fund | 0.43% | 2.32% | -1.55 pp |
Scorecard
- Performance
- High
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 37.2%
- Downside volatility
- 30.5%
- Worst 5% of days
- 3.4%
- Average of that tail
- 4.1%
- Max drawdown (1Y)
- 36.2%
- Below its peak
- 10.6%
Against the market
- Beta vs Nifty 50
- 0.82
- Correlation
- 0.30
- Relative strength (3M)
- -13.2%
- ATR (14)
- 3.6%
Return
- Return 1M
- +9.0%
- Return 3M
- -9.3%
- Return 6M
- +31.4%
- Return 1Y
- +18.5%
- vs 200-day average
- +20.7%
Momentum
- RSI (14)
- 62.6
- MACD histogram
- 309.19
- Stochastic %K
- 91.8
- ADX (14)
- 33.6
- +DI / −DI
- 21.9 / 13.3
- Money flow index
- 52.6
Participation
- Delivery (20d avg)
- 49.5%
- vs its 60-day baseline
- +0.9 pts
- Volume vs 20-day
- -0.5σ
- Close vs day's VWAP
- +0.4%
- 52-week position
- 80 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
2 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- -₹50 Cr
- FCF yield
- -0.2%
- Cash conversion
- 0.95
- Accruals ratio
- 0.006
- Net debt
- ₹289 Cr
- Net debt / equity
- 0.14
- EV / sales
- 12.06
- Capex intensity
- 19.6%
- Revenue CAGR
- 23.3%
- Profit CAGR
- 51.0%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Davuluri Rohini Niveditha Rao Promoter Group · Gift | Sell | 10,000 | ₹0 | 28 Sept 2026 |
Davuluri Saharsh Rao Promoter and Director · Gift | Buy | 10,000 | ₹0 | 28 Sept 2026 |
Davuluri Saharsh Rao Promoters · Pledge Creation | Pledge | 96,000 | ₹116 Cr | 26 Mar 2026 |
Davuluri Saharsh Rao Promoters · Gift | Sell | 12,500 | ₹0 | 5 Mar 2026 |
Deepthi Davuluri Promoter Group · Gift | Buy | 12,500 | ₹0 | 5 Mar 2026 |
Mr. Gannabathula Venkata Krishna Rama Rao Promoters · Gift | Sell | 6,000 | ₹0 | 17 Dec 2025 |
Ms. Kamala Tayaramma Kommula Promoter Group | Buy | 6,000 | ₹0 | 17 Dec 2025 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹34.00
Dividend - Rs 34 Per Share
24 Jul 2026ex-date - dividend₹12.00
Dividend - Rs 12 Per Share
18 Jul 2025ex-date - dividend₹14.00
Annual General Meeting/Dividend - Rs 14 Per Share
12 Jul 2024ex-date - dividend₹10.00
Annual General Meeting/Dividend - Rs 10 Per Share
11 Jul 2023ex-date - dividend₹5.00
Annual General Meeting/Dividend - Rs 5 Per Share
14 Jul 2022ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
29 Jun 2021ex-date - dividend₹2.00
Interim Dividend - Rs 2 Per Share
10 Nov 2020ex-date - otherNot available — not reported in this filing
Annual General Meeting
2 Jul 2020ex-date - dividend₹2.00
Interim Dividend - Rs 2 Per Share
18 Feb 2020ex-date - dividend₹1.20
Annual General Meeting/Dividend - Rs 1.20 Per Share
27 Jun 2019ex-date - otherNot available — not reported in this filing
Annual General Meeting
3 Aug 2018ex-date - otherNot available — not reported in this filing
Annual General Meeting (Date Revised)
21 Dec 2017ex-date - dividend₹2.00
Annual General Meeting/ Dividend - Rs 2/- Per Share
4 Aug 2016ex-date - dividend₹1.50
Annual General Meeting/Dividend Rs 1.50 Per Share
6 Aug 2015ex-date - rightsNot available — not reported in this filing
Rights Issue 4 : 25 @ Premium Rs 194/- Per Equity Share
13 Aug 2014ex-date - dividend₹1.50
Annual General Meeting/Final Dividend Rs.1.50 Per Share And Special Dividend Rs.1.50 Per Share
16 Jun 2014ex-date - dividend₹1.20
Annual General Meeting And Dividend Rs.1.20 Per Share
24 Jul 2013ex-date - otherNot available — not reported in this filing
Annual General Meeting
3 Aug 2012ex-date - rightsNot available — not reported in this filing
Rights 5:12 @ Premium Rs.35/- Per Share
21 Mar 2012ex-date - otherNot available — not reported in this filing
Annual General Meeting
29 Jul 2011ex-date
Company announcements
Copy of Newspaper Publication
Neuland Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the unaudited Financial ....
We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and we would like to inform that the US FDA has issued an EIR ....
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 2026
Press Release
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026
Disclosure under Regulation 30 of SEBI Listing Regulations
Announcement under Regulation 30 (LODR) - Credit Rating
Copy of Newspaper Publication
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Malabar India Fund Ltd
Intimation regarding completion of US FDA Inspection
Transcript of the Earnings Call conducted on August 5, 2026
Intimation about Schedule of Analyst / Institutional Investor Meeting on August 12, 2026
Filed with BSE (scrip 524558); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Rights issue
Neuland Laboratories Limited
30 Sept 2014Read on SEBI - Rights issue
Neuland Laboratories Limited
28 Mar 2014Read on SEBI - Rights issue
Neuland Laboratories Limited
2 Apr 2012Read on SEBI - Rights issue
Neuland Laboratories Limited
30 Mar 2012Read on SEBI - Rights issue
Neuland Laboratories Ltd
3 Oct 2011Read on SEBI
Regulatory orders
- Order
Exemption Order under Regulation 11 of SEBI (SAST) Regulations, 2011 in the matter of Neuland Laboratories Limited
3 Jan 2025Read on SEBI
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 25 Aug from crisil
- Rating update · 13 Jul from fitch
- Rating update · 20 Jun 2025 from crisil
- Rating update · 7 May 2025 from fitch
- Rating update · 10 Mar 2025 from fitch
- Rating update · 27 Mar 2024 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Neuland Laboratories: common questions
Answered from the figures on this page.